Femasys Inc. FEMY
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -89.06%
- 1 year
- -91.70%
5D -0.22 (-14.97%)
- Market cap
- 10.91M
- Revenue (ttm)
- 950.10K
- EPS (ttm)
- -1.79
- Shares out
- 22.90M
- Forward P/E
- -2.33
- YTD return
- -89.06%
- 1-year return
- -91.70%
- 50-day average
- 1.14
- Volume
- 85.91K
- Avg volume
- 132.05K
- Open
- 1.15
- Previous close
- 1.15
- Day's range
- 1.15 – 1.26
- 52-week range
- 1.07 – 20.80
- Beta
- -2.83
- Price target
- 8.25 (+554.8%)
Key statistics
- 200-day average
- 1.22
- Enterprise value
- 16.44M
- Price / sales
- 25.79
- Price / book
- 1.26
- Revenue growth
- -30.90%
- Free cash flow
- -9.24M
- Total cash
- 13.53M
- Total debt
- 7.06M
- Return on equity
- -138.37%
- Short % of float
- 3.01%
Fundamental scorecard
8 of 25 checks passed on FEMY’s reported financials
8of 25 checks passed
- Value 2 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.20 | -0.24 | -0.04 | -20.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.18 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.18 | -0.21 | -0.03 | -16.67% |
| May 9, 2024 | Mar 1, 2024 | -0.22 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.22 | -0.17 | +0.05 | +22.73% |
| Mar 28, 2024 | Dec 1, 2023 | -0.19 | -0.19 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 13, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Femasys Inc.
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- femasys.com
News
Femasys Announces Financial Results for Quarter Ended September 30, 2026 and Provides Corporate Update
Femasys Appoints John Moorhead to Board of Directors
Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs
Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control
Femasys: Launch Is Funded. If The Sales Force Delivers, Then The Company Is In Tall Cotton.
Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo
Analyzing Haemonetics (NYSE:HAE) and Femasys (NASDAQ:FEMY)
Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women's Care
Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio
Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations
Your note
Sign in to keep a note on FEMY — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| CM Management, LLC | 1.86% | 425,000 | 454.75K | Sep 29, 2024 |
| Clear Creek Financial Management, LLC | 1.34% | 306,624 | 328.09K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.90% | 206,483 | 220.94K | Sep 29, 2024 |
| Vanguard Group Inc | 0.84% | 192,667 | 206.15K | Sep 29, 2024 |
| Northern Trust Corporation | 0.39% | 88,421 | 94.61K | Sep 29, 2024 |
| State Street Corporation | 0.25% | 56,369 | 60.31K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.84% | 192,667 | 206.15K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.50% | 114,169 | 122.16K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 34,093 | 36.48K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.12% | 27,036 | 28.93K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.08% | 18,182 | 19.45K | Oct 30, 2024 |
